Skip to content
GenoLensGenoLens

GALM

Chr 2p22.1

galactose mutarotase

MANE:
ENST00000272252.10

Annotations refreshed 9 hours ago.

Predicted protein structure

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

  • Cholestasis

    BIALLELIC, autosomal or pseudoautosomal
  • Likely inborn error of metabolism

    BIALLELIC, autosomal or pseudoautosomal
  • Neonatal cholestasis

    BIALLELIC, autosomal or pseudoautosomal
  • Bilateral congenital or childhood onset cataracts

    BIALLELIC, autosomal or pseudoautosomal

Disease associations (Open Targets)

  • galactosemia 4

    0.78
  • Abnormality of the skeletal system

    0.35
  • hypothyroidism

    0.30
  • nerve plexus disorder

    0.28
  • skin disorder

    0.28
  • Alzheimer disease

    0.28
  • alcohol drinking

    0.28
  • nutritional deficiency disease

    0.24
  • Genu varum

    0.24
  • Genu valgum

    0.24

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Galactose mutarotase

Mutarotase that catalyzes the interconversion of beta-D-galactose and alpha-D-galactose during galactose metabolism (PubMed:12753898). Beta-D-galactose is metabolized in the liver into glucose 1-phosphate, the primary metabolic fuel, by the action of four enzymes that constitute the Leloir pathway: GALM, GALK1 (galactokinase), GALT (galactose-1-phosphate uridylyltransferase) and GALE (UDP-galactose-4'-epimerase) (PubMed:30451973). Involved in the maintenance of the equilibrium between the beta- and alpha-anomers of galactose, therefore ensuring a sufficient supply of the alpha-anomer for GALK1 (PubMed:12753898). Also active on D-glucose although shows a preference for galactose over glucose (PubMed:12753898)

Data sources: HGNC (CC BY 4.0), AlphaFold (CC BY 4.0, Jumper et al. Nature 2021), Genomics England PanelApp (CC BY 4.0), ClinGen, Open Targets (CC0), UniProt.

Not for sole clinical decision-making. Always verify against primary sources.